Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. Ma S, Rosen ST, Winqvist M, Frankfurt O, et al. Leuk Res 2022;122:106945.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ma S, Rosen ST, Winqvist M, Frankfurt O, et al. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. Leuk Res 2022;122:106945.
PMID: 36115087